Aerie Pharmaceuticals Logo

Aerie Pharmaceuticals: Dedicated to Meeting Your Therapeutic Needs

We are an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma, retinal diseases and other diseases of the eye.

Photo of Dr. David L. Epstein (MD), Co-Founder of Aerie Pharmaceuticals Inc.

OUR VISIONaerie® LEGACY

Our VISIONaerie® co-founder, David L. Epstein, M.D. (1943-2014), established Aerie to discover a drug that targets the main cause of elevated IOP in glaucoma – the diseased trabecular meshwork (TM).

MORE
Image of Trabecular meshwork in the eye

THE TRABECULAR MESHWORK

The TM is a natural therapeutic target in open-angle glaucoma. Degenerative changes in the TM may cause a decrease in outflow of aqueous humor, depriving the tissue of nutrients and leading to elevated IOP.

MORE
ROCK inhibitors at the subcellular level that target the trabecular meshwork

ROCK INHIBITION

ROCK inhibitors, representing the first new class of drugs to treat elevated IOP introduced in the United States in more than 20 years, target the TM at the cellular level.

MORE
TOP